Pharmaceutical companies are turning to drug delivery technologies as a strategy to offset patent expiries that threaten to scuttle an estimated $25-30 billion in revenue and slow these companies' 10-15% annual sales growth.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Can new and improved formulations of blockbuster drugs sustain pharmaceutical company revenues? The success or failure of these products will have a strong influence on the future of both pharmaceutical companies and the drug delivery industry.

Drug Delivery: Market Drivers, Technologies, and Companies, a DR Reports publication from Decision Resources, Inc., provides comprehensive coverage:

  -- Describes drug delivery technologies and key products.   -- Profiles leading drug delivery companies.   -- Explores industry trends including alliances and acquisitions.   -- Explains the importance of life-cycle management.   -- Identifies market drivers.   -- Outlines growth strategies.   -- Points to areas of opportunity-for example, drug delivery alternatives      for biopharmaceuticals and chemotherapies.    Products to Watch 

A particular highlight in this report is our review of five "products to watch" for their potential impact on the drug delivery industry, which is now valued at more than $40 billion and promises to be the fastest-growing segment of the pharmaceutical industry.

Drug Delivery: Market Drivers, Technologies, and Companies is available for $5,250 in print and electronic format.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

   In the United States, contact Tim Daley, 781.296.2636 (tel), 781.296.2550    (fax), or tdaley@dresources.com.    In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347    (fax), or fbidart@decisionresources.be.    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel),    +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp. 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X51355061

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, Inc., +1-781-296-2636,
tdaley@dresources.com

Long-Acting Psychostimulant Formulations and Novel Antidepressants Will Boost the Drug-Treated Population for Attention-Deficit/Hyperactivity Disorder, According to a Decision Resources Study

View Now